T Cell Immunotherapy Articles & Analysis
11 articles found
What is CD19 Understanding CD19: Definition and Role in the Immune System CD19, also known as Cluster of Differentiation 19, is a cell surface protein belonging to the immunoglobulin superfamily. It serves as a crucial marker for B cells, playing a pivotal role in the human immune system. While predominantly found on the surface of B cells, CD19 is rarely expressed on other immune cells. Its ...
In the search for innovative and effective ways to target cancer, we are faced with more than just a challenging problem; we are faced with our own cells as opponents. Cancer cells evolve to achieve an optimum of physical fitness, giving them an array of abilities that no cell should possess in a healthy organism. One way to find novel therapies against cancer therefore could imply finding a ...
Chimeric antigen receptor T cells (CAR-T) and T cell antigen receptor chimeric T cells (TCR-T) are currently the "top stream" in adoptive T cell tumor immunotherapy. In particular, CAR-T therapy, which has been approved by the FDA, is rewriting the treatment paradigm of some hematological tumors. However, adoptive T cell therapy remains of little success in solid tumors. The main reason is that ...
Researchers at Massachusetts General Hospital (MGH) have found that interferon gamma receptor (IFNgR) signaling is essential for the susceptibility of CAR-T cell immunotherapy to kill malignant gliomas. The same phenomenon has been observed in other solid tumors. The findings may partially explain why liquid and solid tumors respond very differently to CAR-T cell therapy. Chimeric antigen ...
Adoptive cell transfer (ACT) therapy is one of the most effective therapeutic options for tumor immunotherapy that is currently emerging in clusters. Chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) are the main adoptive immunotherapies in recent years. TCR-engineered T cells express tumor antigen-specific receptors with alpha and beta chains generated from high-quality, ...
Type 1 diabetes (T1D) is a complex T-cell-mediated autoimmune disease that results in the destruction of insulin-producing beta cells and inadequate insulin secretion. Prior to the discovery of insulin in 1921, patients with T1D died within a year or two of diagnosis. Since the discovery and mass production of insulin, T1D is no longer a terminal disease. However, over time, many patients still ...
Immunotherapy, in addition to surgery, chemotherapy, and radiotherapy, has now become the fourth pillar of anticancer treatment, with T cell-based immunotherapy being a successful cancer treatment technique. T cells can be separated into two subpopulations based on the expression of T-cell receptors (TCRs). αβ T cells, expressing expressing αβ TCR, recognize peptide antigens, such as those ...
Researchers at the Children's Hospital of Philadelphia (CHOP) have made a breakthrough in the treatment of aggressive solid cancers, and they have developed a new cancer treatment that targets proteins within tumor cells that are essential for tumor growth and survival, but this has not been possible before. Using the power of large data and advanced computational methods, researchers can ...
Purpose:Although considerable progress has been made withautologous T cell–based therapy in B-cell malignancies, appli-cation in chronic lymphocytic leukemia (CLL) lags behind dueto disappointing response rates as well as substantial toxicitythat is of particular concern in the elderly CLL population.Vg9Vd2-T cells form a conserved T-cell subset with strongintrinsic immunotherapeutic ...
Ryan Pawell is the founder and CEO of Indee Labs, a Berkeley biotech. The mission of Indee Labs is to use microfluidic vortex shedding as a scalable method to deliver CRISPR reagents into cells for developing affordable cell and gene therapies in the future. In our previous blog post, we summarized the work from their latest publication on CRISPR-editing in T cells using microfluidic devices. In ...
The body's immune system is an effective weapon against disease, and immunotherapy of cancer cell research is the current frontier in the treatment of cancer and other diseases. Recently, researchers at Notre Dame University have identified specific features of the reaction of two distinct peptide antigens to a T-cell receptor (TCR), which provides new clues to optimizing molecular structure ...